JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265559

Human TBC1D7 knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

TBC1D7 KO cell line available to order. KO validated by. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 19 bp deletion in exon 2 and 2 bp deletion in exon 2.

View Alternative Names

Cell Migration-Inducing Protein 23, HSPC239, PIG51, TBC1 domain family member 7, TBC7, TCD1D7, dJ257A7.3

2 Images
Sanger Sequencing - Human TBC1D7 knockout HeLa cell line (AB265559)
  • Sanger seq

Unknown

Sanger Sequencing - Human TBC1D7 knockout HeLa cell line (AB265559)

Allele-1 : 19 bp deletion in exon 2.

Sanger Sequencing - Human TBC1D7 knockout HeLa cell line (AB265559)
  • Sanger seq

Unknown

Sanger Sequencing - Human TBC1D7 knockout HeLa cell line (AB265559)

Allele-2 : 2 bp deletion in exon 2.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 19 bp deletion in exon 2 and 2 bp deletion in exon 2

Disease

Adenocarcinoma

Product details

Recommended control: Human wild-type HeLa cell line (ab255928). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265559-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265559 Human TBC1D7 knockout HeLa cell line", "number":"AB265559-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265559-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265559 Human TBC1D7 knockout HeLa cell line", "number":"AB265559-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
TBC1D7
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

TBC1D7 also known as TRE2-BUB2-CDC16 domain family member 7 is a protein with an approximate mass of 25 kDa. This protein acts as a GAP (GTPase-activating protein) for Rab small GTPases which are involved in intracellular trafficking. The expression of TBC1D7 occurs in various tissues such as the liver skeletal muscle and adipose tissue. With its primary role as a GAP TBC1D7 is significant in regulating Rab GTPases' cycling between active and inactive states affecting vesicular transport and cellular logistics.
Biological function summary

TBC1D7 functions as a part of the TSC complex consisting of TSC1 (hamartin) TSC2 (tuberin) and TBC1D7. This complex plays a significant role in cellular growth regulation by inactivating the small GTPase Rheb. This action prevents the overactivation of mTORC1 (mechanistic target of rapamycin complex 1) an important controller of cell growth and proliferation. TBC1D7 adds stability to the TSC complex enhancing its ability to regulate mTORC1 activity effectively demonstrating its key role in cellular metabolic regulation.

Pathways

The involvement of the TBC1D7 protein in the mTOR signaling and insulin signaling pathways is well-documented. Within these pathways TBC1D7 operates along with proteins such as Rheb and mTOR itself. By affecting the TSC complex's inhibitory impact on mTORC1 TBC1D7 influences cell growth survival and metabolism. These pathways are essential for energy sensing and management impacting how cells respond to nutrient availability and growth signals.

TBC1D7 has been linked to conditions like Smith-Kingsmore syndrome and tuberous sclerosis complex. In these disorders the TSC complex's ability to regulate mTOR signaling is disrupted. Mutations or dysregulation of TSC1 TSC2 or TBC1D7 itself can lead to unchecked mTOR activation resulting in abnormal cell growth and proliferation. The relationship between TBC1D7 and these conditions highlights its role beyond cellular mechanics influencing pathological states when its function is altered.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com